Dudediligence.

ANI Pharmaceuticals, Inc

ANIPNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$148.3MSep ’24$190.6MDec ’24$197.1MMar ’25$211.4MJun ’25$227.8MSep ’25$247.1MDec ’25$237.5MMar ’26$266.0MJun ’26
Net income, by quarter
−$24.2MSep ’24−$10.3MDec ’24$15.7MMar ’25$8.5MJun ’25$26.6MSep ’25$27.2MDec ’25$29.5MMar ’26$24.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$216.1M$316.4M$486.8M$614.4M$883.4M
Operating income−$39.8M−$35.3M$47.0M$584,000$111.1M
Net income−$42.6M−$47.9M$18.8M−$18.5M$78.0M
Operating cash flow$3.3M−$31.2M$119.0M$64.0M$185.2M
Free cash flow$765,000−$40.1M$110.1M$47.8M$171.4M
Cash$100.3M$48.2M$221.1M$144.9M$285.6M
Debt$287.4M$286.5M$285.7M$318.3M$309.1M
Shares outstanding12.6M16.3M18.2M21.1M22.5M